CHMP says no to Opdivo + Yervoy for RCC

Bristol-Myers Squibb Co. (NYSE:BMY) revealed in its 2Q18 earnings call that EMA's CHMP plans to issue a negative opinion for Opdivo nivolumab plus Yervoy ipilimumab as first-line

Read the full 274 word article

User Sign In